E-mail a Wiley Online Library Link

P. Rich, B. Sigurgeirsson, D. Thaci, J.-P. Ortonne, C. Paul, R.E. Schopf, A. Morita, K. Roseau, E. Harfst, A. Guettner, M. Machacek and C. Papavassilis Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study British Journal of Dermatology 168

Version of Record online: 30 JAN 2013 | DOI: 10.1111/bjd.12112

What’s already know about this topic?

  •  Conventional systemic therapies for plaque psoriasis have not fully met patient needs.
  •  Biologics, although effective and generally well tolerated, have a still-developing long-term safety profile.
  •  Monoclonal antibodies against interleukin (IL)-17A have shown early promise.

What does this study add?

  •  In this regimen-finding study, the investigational anti-IL-17 monoclonal secukinumab (150 mg subcutaneously) showed significant efficacy for induction and maintenance treatment and was well tolerated in moderate-to-severe plaque psoriasis.
  •  Secukinumab may offer new therapeutic options in plaque psoriasis.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field